title: Vaccine adjuvants: mode of action.
abstract: Vaccines were first introduced more than 200 years ago and have since played a key role in the reduction of morbidity and mortality caused by infectious diseases. Many of the safest and most effective vaccines in use today are based on attenuated live viruses, as they mimic a live infection without causing disease. However, it is not always practical to take this approach, such as when it may not be safe to do so (e.g., for viruses that cause chronic infections such as HIV) or may not be feasible to manufacture (e.g., for viruses that do not grow well in cell culture such as HCV). In addition, it may preferable in some cases to target immune responses toward specific antigens from the pathogen, rather than the entirety of the genome. In these cases, subunit vaccines consisting of antigens purified from the pathogen or produced by recombinant DNA technology are being developed. However, highly purified proteins are typically not inherently immunogenic, as they usually lack the means to directly stimulate the innate immune system, and often require the addition of adjuvants to enhance vaccine potency. Despite more than a century of human use, only a few adjuvants are licensed today. However many adjuvants have been tested in humans and are in advanced stages of development. Much of the early work on adjuvants discovery and development was empirical producing safe and effective products, but without a clear understanding of how they worked. Recent insight into the functioning of the innate immune system has demonstrated its important role in triggering and shaping the adaptive immune response to vaccines.
authors.affiliation: Novartis Vaccines and Diagnostics Inc. , Siena , Italy.
authors.forename: Ennio
authors.initials: E
authors.lastname: De Gregorio
authors.forename: Elena
authors.initials: E
authors.lastname: Caproni
authors.forename: Jeffrey B
authors.initials: JB
authors.lastname: Ulmer
keywords: adjuvant; human; innate immunity; toll-like receptor; vaccine
references.citation: J Gene Med. 2012 Jun;14(6):428-39
references.pmid: 22262664
references.citation: Vaccine. 2011 Jul 12;29(31):4897-902
references.pmid: 21596084
references.citation: Nat Med. 2011 Jul 17;17(8):996-1002
references.pmid: 21765404
references.citation: J Immunol. 2009 Nov 15;183(10):6186-97
references.pmid: 19864596
references.citation: Eur J Immunol. 2008 Aug;38(8):2085-9
references.pmid: 18624356
references.citation: Cell Mol Life Sci. 2008 Oct;65(20):3231-40
references.pmid: 18668203
references.citation: Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):2927-32
references.pmid: 21270336
references.citation: AIDS. 2005 Sep 23;19(14):1473-9
references.pmid: 16135900
references.citation: Immunol Lett. 2003 Jan 22;85(2):85-95
references.pmid: 12527213
references.citation: Vaccine. 2007 Jun 6;25(23):4575-85
references.pmid: 17485153
references.citation: Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10501-6
references.pmid: 18650390
references.citation: Blood. 2010 Dec 9;116(24):5191-9
references.pmid: 20876456
references.citation: J Allergy Clin Immunol. 2001 Aug;108(2):191-7
references.pmid: 11496233
references.citation: Nat Immunol. 2008 Aug;9(8):847-56
references.pmid: 18604214
references.citation: Vaccine. 2006 Jan 9;24(1):20-6
references.pmid: 16198027
references.citation: Curr Pharm Des. 2012;18(16):2305-13
references.pmid: 22390693
references.citation: J Exp Med. 2008 Apr 14;205(4):869-82
references.pmid: 18362170
references.citation: FASEB J. 2012 Mar;26(3):1272-9
references.pmid: 22106367
references.citation: Vaccine. 1999 Oct 14;18(5-6):434-9
references.pmid: 10519932
references.citation: Nat Med. 2011 Apr;17(4):479-87
references.pmid: 21399646
references.citation: J Immunother. 2011 Jan;34(1):1-15
references.pmid: 21150709
references.citation: J Exp Med. 2006 Feb 20;203(2):413-24
references.pmid: 16461338
references.citation: J Immunol. 2008 Sep 15;181(6):3755-9
references.pmid: 18768827
references.citation: Vaccine. 2009 May 26;27(25-26):3401-4
references.pmid: 19200817
references.citation: J Immunol. 2008 Apr 15;180(8):5402-12
references.pmid: 18390722
references.citation: Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15190-4
references.pmid: 16219698
references.citation: Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):E1122-31
references.pmid: 23447566
references.citation: Nature. 2008 Jun 19;453(7198):1122-6
references.pmid: 18496530
references.citation: Comp Immunol Microbiol Infect Dis. 2012 Sep;35(5):443-51
references.pmid: 22560893
references.citation: Vaccine. 2011 Feb 17;29(9):1812-23
references.pmid: 21215831
references.citation: Eur J Immunol. 2004 Jan;34(1):251-62
references.pmid: 14971051
references.citation: Eur J Immunol. 2001 Oct;31(10):2910-8
references.pmid: 11592066
references.citation: Expert Rev Vaccines. 2007 Oct;6(5):685-98
references.pmid: 17931150
references.citation: Pharm Biotechnol. 1995;6:277-96
references.pmid: 7551221
references.citation: Expert Opin Drug Discov. 2012 Sep;7(9):807-17
references.pmid: 22724523
references.citation: Sci Transl Med. 2010 Oct 13;2(53):53ra74
references.pmid: 20944089
references.citation: J Immunol. 2012 Apr 1;188(7):3088-98
references.pmid: 22351935
references.citation: Expert Opin Biol Ther. 2010 Apr;10(4):639-51
references.pmid: 20218923
references.citation: Expert Rev Vaccines. 2012 Mar;11(3):349-66
references.pmid: 22380826
references.citation: Adv Exp Med Biol. 2010;667:111-23
references.pmid: 20665204
references.citation: Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11169-74
references.pmid: 21690334
references.citation: PLoS One. 2011 Jan 26;6(1):e16333
references.pmid: 21298114
references.citation: Vaccine. 2010 Jun 11;28(26):4288-93
references.pmid: 20433806
references.citation: Vaccine. 1996 Feb;14(3):219-25
references.pmid: 8920703
references.citation: Pharm Biotechnol. 1995;6:249-76
references.pmid: 7551220
references.citation: Vaccine. 1996 Oct;14(15):1412-6
references.pmid: 8994315
references.citation: Science. 2006 Dec 22;314(5807):1936-8
references.pmid: 17185603
references.citation: Int Arch Allergy Immunol. 2011;154(4):336-44
references.pmid: 20975285